Galapagos (GLPG) Projected to Post Quarterly Earnings on Wednesday

Galapagos (NASDAQ:GLPG) is expected to issue its Q2 2025 quarterly earnings data after the market closes on Wednesday, July 23rd. Analysts expect the company to announce earnings of ($0.34) per share and revenue of $80.13 million for the quarter.

Galapagos (NASDAQ:GLPG) last released its quarterly earnings data on Wednesday, April 23rd. The biotechnology company reported ($2.47) EPS for the quarter, missing the consensus estimate of ($0.23) by ($2.24). The business had revenue of $97.33 million for the quarter, compared to analyst estimates of $72.22 million. On average, analysts expect Galapagos to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Galapagos Trading Down 0.8%

GLPG stock opened at $30.27 on Wednesday. Galapagos has a 52 week low of $22.36 and a 52 week high of $31.23. The company has a fifty day simple moving average of $28.25 and a two-hundred day simple moving average of $26.32.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Galapagos stock. Jane Street Group LLC boosted its holdings in shares of Galapagos NV (NASDAQ:GLPG) by 2,245.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 110,783 shares of the biotechnology company’s stock after acquiring an additional 115,946 shares during the period. Jane Street Group LLC owned about 0.17% of Galapagos worth $2,783,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 32.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen downgraded shares of Galapagos from a “hold” rating to a “sell” rating in a research note on Friday, April 25th. Five analysts have rated the stock with a sell rating and four have assigned a hold rating to the stock. According to data from MarketBeat, Galapagos currently has a consensus rating of “Reduce” and a consensus price target of $25.33.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.